Solu Therapeutics Funding Round

8/1/2023

Venture Equity

$31,000,000

Seed

The company intends to use the funds to develop the proprietary CyTaC (Cytotoxicity Targeting Chimera) platform and drug candidates which were in-licensed from GSK. In return for the license, GSK received equity in Solu and will receive milestones and royalties on products derived from the CyTaC platform.

Private & Independent

Biopharmaceutical

Undisclosed
Boston, MA Undisclosed
USA

Undisclosed

Solu Therapeutics is a precision-medicine company developing therapeutics to eliminate disease-driving cells. Solu Therapeutics, a precision-medicine company, is developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The proprietary CyTaC (Cytotoxicity Targeting Chimera) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets providing the capability to develop next generation medicines that harness the power of biologics with the vast target binding space of small molecules. Unique characteristics of CyTaC platform molecules include: (i) unlocking new tumor-associated antigens to eliminate cancer cells, (ii) depleting pathogenic immune cells, and (iii) extending the half-life of small molecule antagonists and agonists.